Hoth Therapeutics, Inc. announced on January 21, 2020, that the Company has concluded its 'In-life 28-day animal study' for their BioLexa Platform. The BioLexa Platform is a proprietary antimicrobial therapy designed for the treatment of atopic dermatitis. The therapeutic offers a non-corticosteroid approach treating atopic dermatitis. The condition of the minipigs was observed and checked for dermal observations, dosing, and bioanalysis sample collection. All animals were in good condition with no test item-related dermal observations. Hoth's team also observed the clinical pathology processing and necropsies of the males. There did not appear to be any gross test item-related findings at necropsy and that data will be provided when post testing is concluded. There were no test item related ophthalmic findings, so those exams will not be needed in the recovery animals. Hoth discussed plans to make the reporting phase of the study as efficient as possible and the Company will review the data and phase reports as they are available.